Neuraxpharm Denmark ApS: Financial statements 2025
CVR: 45449688
Source: annual report 2025, Danish Business Authority
25/02/2025 – 31/12/2025
Neuraxpharm Denmark ApS (CVR 45449688) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 404,917 and a net result of DKK 315,835. Equity in the 2025 report amounted to DKK 355,835. The solvency ratio was 45.8%.
- Gross Profit
- DKK 404,917
- Profit/Loss
- DKK 315,835
- Equity
- DKK 355,835
- Total Assets
- DKK 776,344
- Employees
- 0
Official annual report
How creditworthy is Neuraxpharm Denmark ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of February 25, 2025, Johan Anders Magnus Wassén is registered as director of Neuraxpharm Denmark ApS.
As of February 25, 2025, Mark Anthony Slater is registered as director of Neuraxpharm Denmark ApS.
As of February 25, 2025, is registered as an owner of Neuraxpharm Denmark ApS with an ownership share of 100%.
Neuraxpharm Denmark ApS was founded on February 25, 2025.
About Neuraxpharm Denmark ApS
Neuraxpharm Denmark ApS is a Danish company of the type Anpartsselskab based in Herlev, founded in 2025. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Johan Anders Magnus Wassén and Mark Anthony Slater. The company is owned by Neuraxpharm Arzneimittel GmbH. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 404,917 and a net result of DKK 315,835. Equity in the 2025 report amounted to DKK 355,835.